ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Third quarter 2022 revenue grew 33% over third quarter 2021

electroCore Announces Third Quarter 2022 Financial Results

electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.

electroCore Provides Select Third Quarter 2022 Financial Guidance

Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

electroCore, Inc. (NASDAQ:ECOR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the electroCore Second Quarter 2022 Earnings Call.

electroCore, Inc. (ECOR) CEO Dan Goldberger on Q2 2022 Results - Earnings Call Transcript

ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be presenting at the Canaccord Genuity 42nd Annual Growth Conference. Canaccord Genuity 42nd Annual Growth Conference Date: Thursday, August 11, 2022Time: 8:30 AM EDTWebcast: Canaccord Webcast

electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference

ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the second quarter ended June 30, 2022, after the close of the market on Thursday, August 4, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

electroCore to Announce Second Quarter 2022 Financial Results on August 4

ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the second quarter of 2022.

electroCore Provides Select Second Quarter 2022 Financial Guidance

ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days after the initial onset of symptoms of SARS-CoV-2 (COVID) infection1 , 2. These symptoms, such as headache, brain fog, fatigue and gastric distress can bear a striking resemblance to the “central sensitization syndromes,” a group that includes fibromyalgia, chronic fatigue syndrome, and postural orthostatic tachycardia syndrome (POTS). Post-COVID syndrome is likely to occur in upwards of 10% of the population who has been infected with COVID, likely affecting hundreds of millions across the world.

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache.

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be presenting at the H.C. Wainwright Global Investment Conference and LD Micro Invitational Conference.

electroCore to Participate at Upcoming Investor Conferences

electroCore, Inc. (NASDAQ:ECOR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Jeremy Pearlman - Maxim Group Operator Greetings and welcome to electroCore First Quarter 2022 Earnings Conference Call.

electroCore, Inc. (ECOR) CEO Dan Goldberger on Q1 2022 Results - Earnings Call Transcript

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially

electroCore Announces Record First Quarter 2022 Financial Results

ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire™ in patients admitted to the hospital for treatment of COVID-19.

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for further study under the United States Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) program. The program, which is expected to run through September 2023, is funded through the BOOST program as well as the Defense Advanced Research Projects Agency (DARPA).

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical Officer, Dr. Peter Staats, will keynote the Fifth Annual Bioelectronic Medicine Forum on April 5, 2022.

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York

ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be presenting at the 2022 Maxim Virtual Growth Conference.

electroCore to Present at 2022 Maxim Virtual Growth Conference

electroCore, Inc. (ECOR) CEO Daniel Goldberger on Q4 2021 Results - Earnings Call Transcript

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results

Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience

electroCore Announces Changes to its Board of Directors

ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be presenting at the 34th Annual Roth Conference. Details for access to the presentation are as follows:

electroCore to Present at 34th Annual Roth Conference

Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022

electroCore skyrocketed today after the FDA gave its PTSD treatment a breakthrough designation. ECOR stock closed up 60% on the news!

ECOR Stock Alert: Why Is electroCore Soaring Today?

Southwestern Energy

TAL Education Group

Which penny stocks are you watching right now? The post 3 Top Penny Stocks to Add to Your Watchlist in Mid-January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks to Add to Your Watchlist in Mid-January

The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by 31% when compared to sham.

News for ElectroCore Inc Stock (ECOR)